Meanwhile, SONIRE Therapeutics, founded by Satoh Tohru, is advancing high-intensity focused ultrasound (HIFU) technology for treating pancreatic cancer. This non-invasive technique targets cancer cells with ultrasound energy, offering a safer alternative to conventional radiotherapy. SONIRE's HIFU system has been recognized as a breakthrough device by the U.S. FDA and is undergoing clinical trials in Japan. The company aims to secure regulatory approval in Japan by 2027 and in the U.S. by 2028, with plans to expand its application to other cancers. Both startups exemplify Japan's commitment to pioneering medical technology and improving cancer treatment outcomes globally.
Key takeaways:
```html
- The World Health Organization predicts a significant increase in cancer cases by 2050, driven by aging populations and lifestyle factors.
- AI Medical Service in Japan is using AI to improve early detection of gastrointestinal cancers, reducing missed diagnoses.
- SONIRE Therapeutics is developing high-intensity focused ultrasound (HIFU) technology for non-invasive treatment of pancreatic cancer.
- Both companies are gaining international recognition and regulatory approvals, aiming to expand their innovative cancer treatment technologies globally.